Navigation Links
Abeome Forms First Class Scientific Advisory Board

ATHENS, Ga., Sept. 10 /PRNewswire/ -- Abeome Corporation, a Georgia-based biotech company, today announced the formation of its Scientific Advisory Board (SAB) to collaborate on the development of Abeome's ovarian cancer project and to select and guide future therapeutic and diagnostic projects for the company.

The SAB will be led by scientific founder Richard Meagher, PhD, Chief Scientific Officer for Abeome, Distinguished Research Professor at the University of Georgia, and inventor of Abeome's patented monoclonal antibody technology. The SAB will consist of:

Christine Debouck, PhD, President of Ardennes Biosciences LLC and formerly Senior VP in R&D at GlaxoSmithKline, is renowned for her expertise in target validation, disease knowledge and compound characterizations as well as for her broad scientific applications of biotechnology, genomics and biomarker discovery in pre-clinical and clinical development, and biomarker evaluation with an emphasis in oncology and infectious diseases. Dr. Debouck brings 24 years of experience in directing creative science in diverse areas of research.

Jeff Boyd, PhD, Chief Scientific Officer and Sr. VP at Fox Chase Cancer Center in Philadelphia, has an international reputation as one of the leading scientists in the study of molecular genetics of women's cancers. Dr. Boyd was named Distinguished Cancer Scholar by the Georgia Cancer Coalition. His long-term research focus has studied molecular genetics of ovarian cancer with emphasis on hereditary predisposition.

Linda Matsuuchi, PhD, Associate Director of the Life Sciences Institute at the University of British Columbia, has a distinguished research career focused on intracellular trafficking and cell signaling of specific membrane receptors on the cell surface of B lymphocytes, the source of antibody production.

"We are pleased to assemble such an incredibly talented team of scientists to serve on our SAB and to participate in target validation on our ovarian cancer therapeutic project. Their active participation provides Abeome with valuable expertise in pre-clinical and clinical trials, unparalleled knowledge of ovarian cancer pathology, and years of immunology experience specific to monoclonal antibody development," states Abeome CEO, Mike Wanner.

"The company will deploy its monoclonal antibody technology to rapidly develop a pipeline of therapeutic candidates in a number of cancer areas and will benefit by these individual's commitment to our mission. They join an already outstanding group of Abeome scientists, biotech-oriented Board of Directors, and scientific founder, Dr. Richard Meagher to form a team of world-class scientists to insure Abeome's future success."

About Abeome

Abeome Corporation is a biotechnology company dedicated to leveraging its proprietary hybridoma technology to accelerate and improve the development of monoclonal antibodies for life sciences. Abeome owns an exclusive license for the technology from the University of Georgia Research Foundation and has garnered significant support from the Georgia Research Alliance. Its current focus is on developing a cancer therapeutic and diagnostic for ovarian cancer.

For more information on Abeome, visit

SOURCE Abeome Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Satyam Forms Partnership with Sciformix to Provide Comprehensive Drug Safety Management
2. Neogen Forms Mexican Subsidiary
3. BioStorage Technologies Forms Scientific Advisory Board with Leading Life Science Experts
4. American Oriental Bioengineering Forms Science and Technology Advisory Committee
5. IC Sciences Announces Launch of ICS Advisory Services Intellectual Property Platforms Available Through ICSciences Alliance
6. Agrenco Informs Sale of Biodiesel at ANP Auction
7. Caliper Life Sciences Forms Alliance With Horizon Discovery to Provide Enhanced Solutions for Cancer Research Based on Isogenic Cell Lines
8. International Federation of Clinical Chemistry Forms Partnership With the Labs Are Vital(TM) Initiative
9. Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team
10. febit Forms Scientific Advisory Board
11. Microchip Biotechnologies, Inc. Collaborating With Stanford University on Developing a Front End Microfluidic-Based Sample Preparation System for Pyrosequencing Platforms
Post Your Comments:
(Date:6/23/2016)... June 23, 2016 A person commits a crime, ... scene to track the criminal down. An outbreak ... and Drug Administration (FDA) uses DNA evidence to track down ... Sound far-fetched? It,s not. The FDA has increasingly used ... investigations of foodborne illnesses. Put as simply as possible, whole ...
(Date:6/23/2016)... June 23, 2016  The Prostate Cancer Foundation (PCF) is pleased ... and faster cures for prostate cancer. Members of the Class of 2016 were ... Read More About the Class of 2016 PCF Young ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, ... of the Supplyframe Design Lab . Located in Pasadena, Calif., the Design ... of how hardware projects are designed, built and brought to market. , The ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
Breaking Biology Technology:
(Date:5/12/2016)... 2016 , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/15/2016)... , April 15, 2016  A new partnership ... more accurate underwriting decisions in a fraction of ... competitively priced and high-value life insurance policies to ... With Force Diagnostics, rapid testing (A1C, ... data readings (blood pressure, weight, pulse, BMI, and ...
Breaking Biology News(10 mins):